山之内公司的新一代抗胆碱能药Vesicare (solifenacin ,暂译为 :索非那新 ) ,作为治疗膀胱过动症已首次在荷兰批准。山之内欧洲公司说 ,在欧洲其他国家上市的时间取决于欧盟各国对荷兰批准的认可。在欧洲 ,在年过 4 0岁的人群中有超过 16 %的人患有膀胱过动症 ,总共有 2 5 0 0? The new generation of mountainous company anticholinergic Vesicare (solifenacin, provisional translation: solifenacin), as the treatment of overactive bladder has been approved in the Netherlands for the first time. Within the mountains of Europe, the company said that listing in other European countries depends on the timing of EU approvals for the Netherlands. In Europe, over 16% of over-40s have overactive bladder, a total of 2.500%